8-K: Senti Biosciences Secures $40M Convertible Note Financing

Senti Biosciences Holdings, Inc. announced a private placement of up to $40 million in senior secured convertible notes, with its largest stockholder, Celadon Partners, providing the initial $10 million.

Summary

• Senti Biosciences Holdings, Inc. (SNTI) entered into a Securities Purchase Agreement for a private placement of up to $40.0 million in Senior Secured Convertible Notes.
• The investor is an entity affiliated with Celadon Partners SPV 24, the company's largest stockholder, holding more than five percent of outstanding capital stock.
• The first tranche of $10.0 million in Notes is to be issued, subject to closing conditions, including the consummation of a holding company reorganization, which occurred on April 24, 2026.
• A second tranche of up to $30.0 million may be issued at Celadon's discretionary election, contingent on the execution of definitive documents for a potential Contingent Value Right (CVR) Transaction within 30 days of the initial Notes closing.
• The CVR Transaction, if consummated, could pay out up to an aggregate of $60.0 million in cash to Senti's stockholders, subject to the achievement of certain regulatory and sales milestones for product candidate SENTI-202.
• Proceeds from the Notes will be used for general corporate purposes and to advance CMC and clinical trials for SENTI-202.
• Senti Holdings agreed to pay Celadon a 3.0% structuring discount on the aggregate principal amount of Notes purchased by Celadon and any purchasers brought in by Celadon.
• The Notes are senior, secured indebtedness, guaranteed by the Company and its direct and indirect subsidiaries, with a first priority lien on all current and future assets.
• The Notes mature six months after the initial closing date and require a 200% cash payment of outstanding principal and accrued interest if not converted or exchanged.
• The initial conversion/exchange price is $0.6261 per share, subject to customary adjustments, including a full-ratchet anti-dilution adjustment if common stock is issued at a lower price.
• Stockholder approval is required by August 31, 2026, to issue shares underlying the Notes without the 19.99% Exchange Cap, with Celadon agreeing to vote in support.
• Upon an Event of Default, holders can demand redemption at the greater of 200% of outstanding principal or a formula based on stock price, with a 12.0% annual interest rate accruing during default.
• Assuming the initial $10.0 million issuance, stockholder approval, and immediate exchange, Celadon would beneficially own 54.6% of the company's outstanding common stock.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a necessary but highly expensive and potentially dilutive financing, reflecting significant challenges in securing capital under more favorable terms. While it provides immediate funding, the terms are heavily skewed towards the investor, Celadon Partners.

Positives

• Secured up to $40.0 million in financing, with an initial $10.0 million, to support general corporate purposes and advance the SENTI-202 product candidate.
• The financing is provided by Celadon Partners, the company's largest stockholder, indicating continued support from a major investor.
• The potential CVR Transaction offers an additional $60.0 million payout to stockholders if SENTI-202 achieves regulatory and sales milestones.
• The Notes are secured by a first priority lien on company assets, providing security for the investor.

Negatives

• The Notes carry a significant redemption premium of 200% of outstanding principal at maturity or upon an Event of Default, which is highly unfavorable for the company.
• The full-ratchet anti-dilution adjustment mechanism is extremely dilutive to existing shareholders if future equity is issued at a lower price.
• Celadon Partners, the largest stockholder, will increase its beneficial ownership to 54.6% after the initial tranche and stockholder approval, potentially consolidating control.
• A 3.0% structuring discount is payable to Celadon, adding to the cost of financing.
• The requirement for stockholder approval by August 31, 2026, for the issuance of shares beyond the Exchange Cap introduces uncertainty and a potential delay.
• The short maturity date of six months for the Notes creates a near-term refinancing or conversion pressure.

Risks

• The issuance of the Notes or the potential CVR Transaction may not be completed in a timely manner or at all, which could adversely affect the business and stock price.
• Failure to satisfy the conditions to the consummation of any Notes, including the execution of definitive documents related to the potential CVR Transaction.
• The occurrence of any event, change, or other circumstance that could give rise to the termination of the Securities Purchase Agreement.
• The effect of the announcement or pendency of the transactions described herein on the business relationships, operating results, and business generally of the Company.
• Risks that the transactions described herein disrupt current plans and operations of the Company and potential difficulties in employee retention as a result of the proposed transactions.
• Risks related to diverting management's attention from the Company's ongoing business operations.
• The outcome of any legal proceedings that may be instituted against the Company related to the proposed transactions.
• Restrictions during the pendency of the proposed transactions that may impact the Company's ability to pursue certain business opportunities or strategic transactions.
• Additional or unforeseen effects from the global economic and geopolitical climate, and catastrophic events, including, but not limited to, acts of terrorism or continuation or outbreak of war or hostilities, may amplify many of these risks.

Future Outlook

The company intends to use the proceeds from the financing to advance its product candidate SENTI-202 through CMC and clinical trials. The potential CVR Transaction offers a future payout to stockholders based on SENTI-202's regulatory and sales milestones. The company is also seeking stockholder approval for the issuance of shares underlying the Notes and the CVR Transaction.

Management Comments

• The Company agreed to use substantially all of the net proceeds from the sale of the Notes for general corporate purposes and to advance CMC and clinical trials for their product candidate, SENTI-202.

Industry Context

StockSavvy.ai notes that this financing round is critical for Senti Biosciences, a biotechnology company, to continue the development of its product candidate SENTI-202. The involvement of a major existing stockholder like Celadon Partners, coupled with a CVR mechanism tied to clinical and commercial success, reflects a common strategy in the high-risk, high-reward biotech sector to align investor interests with product development milestones. The dilutive terms, including the 200% redemption premium and full-ratchet anti-dilution, suggest the company faced challenges in securing less onerous financing, which is not uncommon for early-stage or struggling biotech firms.

Comparison to Industry Standards

• The 200% redemption premium on the convertible notes is significantly higher than typical convertible debt terms, which usually range from 100-120% of principal. This indicates a high cost of capital for Senti Biosciences, likely due to perceived risk or limited alternative financing options.
• The full-ratchet anti-dilution protection is a very strong investor-friendly term, rarely seen in standard venture or public market financings unless the company is in a distressed situation or has very limited leverage. It provides maximum protection against future dilutive equity raises, but at a severe cost to existing shareholders.
• The beneficial ownership threshold of 19.99% for the Exchange Cap without stockholder approval is standard for Nasdaq listing rules, but the need for stockholder approval to exceed this, combined with Celadon's increased ownership to 54.6%, highlights a potential shift in control and governance. This level of control by a single investor is more common in private equity or distressed asset scenarios than in typical public company financings.
• The 3.0% structuring discount is within the range of typical placement agent or advisory fees for private placements, though on the higher end for a direct deal with an existing major investor.

Corporate Governance

Related Party Transactions

• The Investor is an entity affiliated with Celadon Partners SPV 24, which is the Company's largest stockholder and a holder of more than five percent of the Company's outstanding capital stock.
• Senti Holdings agreed to pay Celadon 3.0% of the aggregate principal amount of the Notes purchased by Celadon and any purchaser of Notes brought in by Celadon.
• Celadon agreed to vote in support of the proposal to approve the Company's issuance of shares of its common stock underlying the Notes without giving effect to the Exchange Cap.
• Directors and executive officers of the Company, as well as Celadon, entered into a voting agreement to vote all shares of the Company's common stock they hold in favor of each stockholder proposal related to the CVR Transaction and the issuance of shares underlying the Notes.

Stakeholder Impact

• Shareholders: Face significant dilution from the convertible notes, especially with the full-ratchet anti-dilution. The 200% redemption premium is a substantial cost to the company, indirectly impacting shareholder value. The potential CVR offers a future upside tied to SENTI-202's success. Celadon's increased ownership to 54.6% shifts control.
• Employees: The financing provides capital to continue operations and advance SENTI-202, potentially securing jobs. However, forward-looking statements mention risks of potential difficulties in employee retention due to the proposed transactions.
• Creditors: The Notes are senior secured indebtedness with a first priority lien on assets, providing strong protection for the noteholders (Celadon). This could subordinate other unsecured creditors.
• Management: Their attention may be diverted by the transactions, and they are bound by a voting agreement to support the proposals.

Next Steps

• Execute definitive documents for the potential CVR Transaction within 30 days of the Initial Notes closing.
• Solicit stockholder approval for the issuance of shares underlying the Notes without the Exchange Cap by August 31, 2026.
• File relevant materials with the SEC, including a preliminary proxy statement on Schedule 14A, for the Subject Transactions (Notes issuance beyond Exchange Cap and potential CVR Transaction).
• Mail proxy materials to stockholders for the annual or special meeting related to the Subject Transactions.
• File one or more resale registration statements on Form S-3 for the shares issuable upon exchange of the Notes.
• Advance CMC and clinical trials for the product candidate SENTI-202.

Key Dates

Recommendation

The terms of this financing are highly unfavorable for existing shareholders. The 200% redemption premium and the full-ratchet anti-dilution clause are extremely punitive, indicating a distressed financing scenario. While the capital infusion is necessary for operations and SENTI-202 development, the cost is exceptionally high, and the significant increase in Celadon's control (54.6% beneficial ownership) further diminishes the influence and potential upside for other shareholders. The short 6-month maturity adds immediate pressure. These terms suggest a significant erosion of shareholder value and a challenging path forward for the company.

Keywords

Senti Biosciences, SNTI, Convertible Notes, Private Placement, Celadon Partners, Biotechnology, Pharmaceuticals, SEC Filing, 8-K, Financing, SENTI-202, Clinical Trials, Corporate Governance, Dilution, Contingent Value Rights, CVR Transaction, Nasdaq Capital Market